Technical analysis indicates that selling in Oncosil (ASX: OSL) is overdone, likely driven in the past by the broader performance of the ASX and more recently by higher interest rates and inflation. However, the sell-off will taper soon as the chart suggests that selling could likely be overdone. This represents a very good buy opportunity for investors and with expansion and commercialization tend to continue in 2024, the stock could be gearing for a reversal.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.010(0.86%) |
Mkt cap ! $21.74M | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.17 | $1.14 | $80.47K | 69.48K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2150 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 7380 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |